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Peroxisome proliferator-activated receptor  coactivator-1
(PGC-1) is a transcriptional coactivator involved in several aspects
of energy metabolism. It is induced or activated under different
stimuli in a highly tissue-specific manner and subsequently part-
ners with certain transcription factors in those tissues to execute
various biological programs. In the fasted liver, PGC-1 is induced
and interacts with hepatocyte nuclear factor 4 (HNF4) and other
transcription factors to activate gluconeogenesis and increase
hepatic glucose output. Given the broad spectrum of liver genes
responsive to HNF4, we sought to determine those that were spe-
cifically targeted by the combination of PGC-1 and HNF4. Co-
expression of these two molecules in murine stem cells reveals a
high induction of mRNA for apolipoproteins A-IV and C-II. Forced
expression of PGC-1 in mouse and human hepatoma cells
increases the mRNA of a subset of apolipoproteins implicated in
very low density lipoprotein and triglyceridemetabolism, including
apolipoproteins A-IV, C-II, and C-III. Coactivation of the apoC-III/
A-IV promoter region by PGC-1 occurs through a highly con-
servedHNF4 response element, the loss of which completely abol-
ishes activation by PGC-1 and HNF4. Adenoviral infusion of
PGC-1 into live mice increases hepatic expression of apolipopro-
teins A-IV, C-II, andC-III and increases serum and very low density
lipoprotein triglyceride levels. Conversely, knock down of PGC-1
in vivo causes a decrease in both apolipoprotein expression and
serum triglyceride levels. These data point to a crucial role for the
PGC-1/HNF4 partnership in hepatic lipoprotein metabolism.
The liver is central to systemic nutrient metabolism. It regulates
both catabolic and anabolic processes that maintain proper blood
levels of protein, carbohydrate, and lipid. The liver responds to
blood-borne hormones and neurotransmitters, executing biological
programs to ensure that the energy demands of peripheral tissues are
satisfied. Many of these programs exert metabolic changes through
the activation or induction of specific transcription factors, which in
turn increase the expression of key enzymes or other downstream
regulators.
The peroxisome proliferator-activated receptor  (PPAR)4 coacti-
vator-1 (PGC-1) (1) has emerged as an important regulator of several
liver functions. It positively regulates hepatic heme biosynthesis and
links fasting to acute attacks of porphyria (2). PGC-1 induces CYP7A1,
the rate-limiting enzyme of bile acid synthesis (3–5). It also partners
with liver X receptor  and farnesoid X receptor in modulating choles-
terol and triglyceride metabolism (6, 7). In the hepatic response to fast-
ing, PGC-1 coordinates the induction of genes involved in gluconeo-
genesis, fatty acid oxidation, and ketogenesis (8, 9). Its coactivation of
the liver-enriched transcription factors HNF4 and FOXO1, as well as
the glucocorticoid receptor, results in the induction of gluconeogenic
enzymes and increased hepatic glucose output (10, 11). The functional
loss or genetic knock out of either HNF4 or FOXO1 completely abro-
gates the ability of PGC-1 to activate hepatic gluconeogenesis.
PGC-1 interacts tightly with HNF4 in vitro and strongly coactivates
this transcription factor on the phosphoenolpyruvate carboxykinase
and glucose-6-phosphatase promoters (8, 10).
HNF4 has been recognized as a broad regulator of liver function (12,
13). Ectopic expression ofHNF4 in de-differentiated hepatoma cells or
fibroblasts induces both a morphology and genetic markers character-
istic of hepatic epithelium (14, 15). Although the total knock out of
HNF4 is embryonic lethal due to defects in gastrulation (16), embryos
lacking HNF4 can be rescued in midgestation through tetraploid
complementation (17). Analysis of E12.0 fetuses null for HNF4 shows
that a lack of HNF4 impairs differentiation into a fully functional
hepatic parenchyma that expresses its normal complement of serum
and metabolic factors, such as apolipoproteins and fatty acid-binding
proteins (18). Conditional knock out of the gene in the liver through a
tissue-specific cre-lox system produces viable offspring that suffer from
severe defects in lipid homeostasis; they accumulate lipid in the liver and
exhibit reduced serum triglyceride levels (19). It is clear that the tran-
scriptional targets of HNF4 are numerous and varied. In fact, using
chromatin immunoprecipitation in human hepatocytes combined with
promoter microarrays, HNF4 localizes to 12% of 13,000 promoters
examined (20).
Given the important functional interaction of PGC-1 with HNF4
and the broad roles of these twomolecules in hepatic function, it is quite
likely that their partnership influences multiple aspects of liver metab-
olism beyond that which has been described. Through microarray
analysis, we now identify a subset of apolipoproteins as transcrip-
tional targets that are particularly dependent on the cooperative
action of PGC-1 and HNF4. Adenoviral infusion of PGC-1 into
live mice results in the hepatic induction of these apolipoproteins
and a concomitant increase in serum and VLDL triglyceride. Knock
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down of PGC-1 via adenoviral RNAi decreases apolipoprotein
mRNA and serum triglyceride levels. These data indicate that the
PGC-1/HNF4 partnership plays a critical role in hepatic lipopro-
tein synthesis and export.
EXPERIMENTAL PROCEDURES
Microarray Analysis—Affymetrix array hybridization and scanning
were performed by the Core Facility at Dana-Farber Cancer Institute
using Murine 430 2.0 chips. Array data were analyzed with d-CHIP
software.
RNA Isolation and Analysis—Total RNAwas isolated from liver or cul-
tured cells using TRIzol reagent (Invitrogen) according to themanufactur-
er’sprotocol. Forquantitative real-timePCRanalysis, 2gof totalRNAwas
reverse transcribed with Moloney murine leukemia virus reverse tran-
scriptase (Invitrogen) and random hexamer primers (Roche Applied Sci-
ence). Relative mRNA abundance normalized to 18 S rRNA levels was
determined with theCtmethod after amplification using an iCycler iQ
real-time PCR detection system (Bio-Rad) and SYBRGreen (Bio-Rad). For
Northern hybridizations, 20 g of each sample of RNA was resolved on a
formaldehyde gel, transferred to nylon membrane using a TurboBlotter
(Schleicher & Schuell), and hybridized with 32P-labeled gene-specific
probes. Hybridization to ribosomal protein 36B4was included as a loading
control.
Animal Experiments—All animal experiments were performed accord-
ing to procedures approved by the Institutional Animal Care and Use
Committee. Animals were fed standard rodent chow and housed in a
controlled environment with 12-h light and dark cycles. Fasts were
started at the beginning of a dark cycle, and mice were deprived of food
for the indicated amount of time before being sacrificed.
Adenoviral Infection—Adenoviral GFP and PGC-1 have been
described previously (54). An adenoviral vector encoding HNF4 was
generated by cloning an HNF4 cDNA into AdTrack-CMV (Invitro-
FIGURE 1. The ectopic combination of PGC-1 and HNF4 induces apolipoproteins in F9 cells. RNA taken from F9 teratocarcinoma cells infected with adenoviruses encoding
GFP, PGC-1, HNF4, or PGC-1 plus HNF4was subjected to quantitative PCR analysis. Primer sets were used that amplify a select group of apolipoproteins and other liver genes.
Graphs represent -fold change over gene expression in cells receiving only GFP.
TABLE 1
Highest scoring targets of AdPGC1 AdHNF4 co-expression
GFP alone
Fold expression over GFP
PGC-1 alone HNF4 alone PGC-1HNF4
Apolipoprotein C-II 1 1 18.51 810.56
Aminoacylase 1 1 31.21 82.36 674.17
RIKEN cDNA 4932432N11 gene 1 36.6 1 270.45
Purinergic receptor P2X, ligand-gated ion channel, 3 1 1 201.21 229.43
Apolipoprotein A-IV 1 1 1 156.09
Retinol dehydrogenase 7 1 1 2.35 118.08
C-type lectin-related f 1 4.02 2.11 105.13
PGC-1 1 43.08 NA 94.08
G0/G1 switch gene 2 1 NA 5.85 71.01
HNF4 1 4.75 67.1 70.52
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gen). Cultured cells were infected with the indicated adenovirus at a
multiplicity of infection of 50 at 90% confluence. 36 h after infection,
cells were harvested and their RNA isolated. Female, 8-week-old C57
BL/6 mice were transduced with CsCl-purified adenovirus via tail vein
injection. Mice were each tail vein injected with 0.2 OD of adenovirus
(2 1011 viral particles/mouse). Four days later, they were subjected
to a 24-h fast. The mice were sacrificed on the fifth day and their livers
and plasma harvested.
Cell Culture, Transfections, and Reporter Gene Assays—F9 teratocar-
cinoma cells were cultured on gelatinized plates in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum. H2.35
mouse hepatoma cells were kept in Dulbecco’s modified Eagle’s
medium supplemented with 4% fetal bovine serum and 1 M dexam-
ethasone. HepG2 cells were cultured in 10% fetal bovine serum in Dul-
becco’s modified Eagle’s medium. Cells were transfected in 6-well
dishes at 70% confluence using Superfect (Qiagen) according to the
manufacturer’s protocol. Each transfection involved a 1:1:10 ratio of
reporter gene:transcription factor(s):coactivator for a total of 3.6 g of
DNA. Equal amounts of DNA were used for all transfection combina-
tions by using appropriate vector DNA. For reporter gene assays, cells
were harvested 24 h after transfection. Luciferase levels were deter-
mined and normalized to -galactosidase expression. All transfection
experiments were repeated at least three times in triplicate.
Site-directed Mutagenesis—Site-directed mutagenesis of the apoC-
III/A-IV luciferase reporter (28) was performed using overlapping
primers and the Expand Long Template PCR system (Roche Applied
Science). HNF4-binding Site 1 was mutated from 5-TGGGCAAAG-
GTCA-3 to 5-TGGGCAAtGcgCA-3, which introduced an FspI site.
Site 2wasmutated from5-TGGACCTTGTTCT-3 to 5-TGGACCT-
TcTaga-3, which introduced an XbaI site.
Chromatin Immunoprecipitation—Experiments were performed using
a chromatin immunoprecipitation kit (EZ ChIP) following the manufac-
turer’s protocol (Upstate Biotechnology). H2.35 cells were transfected
in 15-cm plates at 70% confluence with plasmids expressing GFP,
FLAG-tagged PGC-1, or FLAG-tagged PGC-1 plus HNF4. Two
days later cells were harvested, DNA-protein complexes cross-linked in
formaldehyde, and immunoprecipitation reactions performed using
M2 anti-FLAG resin (Sigma). After reverse cross-linking, DNA was
purified by spin columns and subsequently analyzed by PCR.
Triglyceride Measurements and Lipoprotein Fractionation—Total
serum triglyceride was measured using a colorimetric assay kit (337;
Sigma). For fractionation experiments, serum was diluted 1:1 (v/v)
with phosphate-buffered saline and centrifuged to remove any
debris. 100 l of diluted sample was injected into a Superose 6 HR
10/30 gel filtration column for analysis of plasma lipoproteins, per-
formed using a fast protein liquid chromatography system (Pharma-
cia A¨KTA) at 4 °C (55). Samples were eluted at a flow rate of 0.4
ml/min in buffer containing 0.05 M phosphate and 0.15 M NaCl, pH
7.0. Fractions of 0.3 ml were collected for analysis. Triglyceride levels
in each fraction were measured enzymatically using an Infinity Trig-
lyceride (GPO-Trinder) kit (Sigma).
RESULTS
Combined Expression of PGC-1 and HNF4 Induces Apolipopro-
teins in Cultured Cells—To determine the genes that are dependent
upon cooperation between PGC-1 and HNF4, we exogenously
expressed these two molecules in F9 teratocarcinoma stem cells using
adenoviral vectors. These cells have the ability to produce all three germ
layers and have been used heavily as a model system for differentiation
(21). Table 1 is a partial list of the genes most highly induced by the
combined ectopic expression of PGC-1 and HNF4 as determined by
microarray analysis. Apolipoproteins C-II and A-IV are highly induced
by the combination of HNF4 and PGC-1, whereas either molecule
alone does not induce them to nearly the same extent. Other apoli-
poproteins detected by themicroarray are not significantly increased by
these two molecules (supplemental Table S1).
To confirm the results of the microarray analysis, we analyzed the
RNA from the F9 cells with quantitative PCR. As shown in Fig. 1,
apoC-II and apoA-IV are highly induced by PGC-1 andHNF4, much
more so than by either protein alone. Interestingly, apoA-I and apoC-III
are also significantly induced by PGC-1 and HNF4 in this context,
despite their relatively low expression in the arrays.HNF4 activates the
apoB promoter (22), and although there is a 20-fold induction of apoB
by HNF4 alone, PGC-1 only further augments this by a modest
2-fold. The expression of apoE, another target of HNF4 (23), is not
increased in the presence of ectopic PGC-1 and HNF4. Likewise,
although the epithelial marker E-cadherin is expressed in response to
forced HNF4 expression in fibroblasts (14), it fails to be activated in
these cells by the co-expression of PGC-1 and HNF4. In summary,
PGC-1 robustly coactivates a subset, but not all, of the downstream
targets of HNF4.
Apolipoprotein biosynthesis is most abundant in the liver in vivo. To
examine the effects of PGC-1 andHNF4 in cells derived from liver,we
exogenously expressed the two molecules in H2.35 mouse hepatoma cells
through adenoviral transduction and subsequently harvestedRNA.North-
ern analysis in Fig. 2A shows that the mRNAs for apolipoproteins A-IV,
C-II, and C-III are induced to detectable levels only in the presence of both
PGC-1 and HNF4. ApoA-IV and apoC-II are expressed 11-fold over
their levels with HNF4 alone, whereas apoC-III is increased 14-fold as
FIGURE 2. The ectopic combination of PGC-1 and HNF4 induces apolipoproteins
in hepatoma cells. A, H2.35 mouse hepatoma cells were infected with the indicated
adenoviruses, and their RNA was analyzed by Northern blotting with radiolabeled
mouse cDNA probes. 36B4was blotted as a loading control. B, HepG2 human hepatoma
cells were infected with the indicated adenoviruses, and their RNA was analyzed by
Northern blottingwith radiolabeled human cDNAprobes. 36B4was blotted as a loading
control.
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FIGURE 3. PGC-1 coactivates and is recruited to the apoC-III/A-IV promoter region. A, H2.35 cells were transfected with an apoC-III/A-IV luciferase reporter and plasmids
encoding the transcription factors estrogen-related receptor  (ERR), FOXO1, GR, HNF4, PPAR, or PPAR. Reporter activity was measured for each of these transcription factors
in the absence and presence of PGC-1 and depicted as –fold change over the first lane (vector alone). Transfections were repeated at least three times in triplicate. B, a diagram of
the apoC-III/A-IV intergenic region. The full-length mouse promoter is 6 kb long, and two previously identified HNF4 response elements are depicted. Conservation of these sites
between human and mouse genomes is also shown. C, H2.35 cells were transfected with plasmids expressing GFP, FLAG epitope-tagged PGC-1, or a combination of HNF4 and
tagged PGC-1. Following formaldehyde cross-linking, chromatin immunoprecipitation assayswere performedusing anti-FLAG resin. Co-immunoprecipitatedDNAand 5%of input
DNAwere used as template for PCR primers flanking site 1, site 2, and a control region on chromosome 9 downstream of the apoA-IV gene. All PCR reactions were carried out to 23
cycles.D, H2.35 cellswere transfectedwith PGC-1, HNF4, andeither awild-typeormutant apoC-III/A-IV luciferase reporter. HNF4-binding sites 1 and2weremutated asdescribed
under “Experimental Procedures.” PGC-1 coactivation of HNF4was measured on each of the different reporters and depicted as –fold change over the first lane (PGC-1 alone).
Transfections were repeated at least three times in triplicate.
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measured by quantitative PCR (supplemental Table S2). Unlike its effect in
F9 cells, ectopic HNF4 in H2.35 cells is, alone, sufficient to increase apoE
levels.However, the additionofPGC-1doesnot significantly enhance this
induction. Likewise, HNF4 alone is able to induce apoB by 18-fold, and
PGC-1 does not further increase its levels (supplemental Table S2). PGC-
1, a closely related homolog of PGC-1 that has been shown to regulate
hepatic lipid synthesis and export (24), fails to induce these same genes.
This is most likely due, at least in part, to the fact that PGC-1 coactivates
HNF4 poorly (25).
To determine whether PGC-1-mediated induction of apolipopro-
teins occurs within human cells as well as those from mouse, we
expressed PGC-1 in HepG2 hepatoma cells. As in the H2.35 cells,
PGC-1 is able to induce the same subset of apolipoproteins (Fig. 2B).
However, in contrast to its expression in H2.35 cells, ectopic PGC-1 in
HepG2 cells is alone sufficient to activate expression of these genes. In
fact, adenoviral PGC-1 is muchmore effective in inducing these genes
than is adenoviral HNF4. For example, the level of apoA-IV is more
than 30 times higher in the setting of adenoviral PGC-1 than in the
presence of adenoviral HNF4 (supplemental Table S3). This is likely
the result of a high endogenous level of HNF4 (Fig. 2B) through which
the exogenously expressed PGC-1may act.
PGC-1 Coactivates HNF4 on the apoC-III/A-IV Promoter—The
apoA-IV and apoC-III genes are separated in the mouse and human
genomes by an 6-kb intergenic region (26). Because apoA-IV and
apoC-III are transcribed in opposite directions, this intergenic region
serves as a common 5-flanking sequence for both genes (27). To test
whether this region is responsive to PGC-1 coactivation ofHNF4, we
transfected plasmids encoding these two factors along with an apoC-
III/A-IV promoter luciferase construct into H2.35 hepatoma cells.
Recent studies in intestinal epithelial cells report that PGC-1 coacti-
vates estrogen-related receptor  on this promoter construct (28). Fig.
3A shows that PGC-1 robustly coactivates HNF4 on this reporter to
nearly 400-fold over base line. No significant activation occurs when
PGC-1 is co-expressedwith other liver transcription factors, including
a constitutively active allele of FOXO1, glucocorticoid receptor (GR),
PPAR, and PPAR (Fig. 3A). Previous reports have shown that
PGC-1 coactivates these factors in other contexts (1, 11, 29).
We next identified the HNF4 response elements through which
PGC-1 exerts its effects. Fig. 3B shows two previously characterized
HNF4-binding sites, labeled sites 1 and 2, located in the proximal
promoters of apoC-III and apoA-IV, respectively (30, 31). These two
direct repeats (DR-1) were also identified by NUBIScan, a computer
algorithm that predicts DNA recognition sites for nuclear receptors
(32). Site 1 is a DR-1 that is 100% conserved betweenmouse and human.
Chromatin immunoprecipitations were performed with antibodies
against FLAG epitope-tagged PGC-1, expressed alone or with HNF4
in H2.35 hepatoma cells. Only the immunoprecipitates containing
cross-linked complexes of PGC-1 and HNF4with genomic DNA are
enriched with fragments encompassing site 1 and site 2, indicating that
PGC-1 is recruited to both of these sites through HNF4 (Fig. 3C).
Primers that amplify a control region on chromosome 9 downstream
from the apoC-III/apoA-IV gene cluster show no PGC-1-specific
enrichment.
To test the functional significance of these two putative HNF4-
response elements, we disrupted one of the two half-sites within each
DR-1 through site-directed mutagenesis. Whereas mutation of site 2
leaves PGC-1 coactivation completely intact, mutation of site 1 utterly
abolishes the PGC-1 effect (Fig. 3D). The absolute loss of response to
PGC-1 when site 1 is mutated is observed in both the full-length
reporter as well as in a truncated version containing 700 bp of apoC-III
proximal promoter (data not shown). Taken together, these data show
that PGC-1 directly coactivates HNF4 on the apolipoprotein C-III/
A-IV intergenic region through an HNF4-responsive element.
Apolipoproteins A-IV andC-II Are Induced in Fasted Liver—Wenext
investigated the physiological significance of PGC-1-mediated induc-
tion of apolipoproteins. Because PGC-1 is an integral part of the
hepatic fasting response, we looked at the expression of apolipoproteins
in fasted mice. Previous reports demonstrate mild increases in apoA-I
during fasting and more robust increases in apoA-IV (33). Northern
blotting in Fig. 4 shows that the genes for PGC-1 and apolipoproteins
A-IV and C-II are indeed induced under 6- and 24-h food deprivation.
Whereas apoC-II is increased roughly 2-fold at the 24-h time point,
apoA-IV is induced over 70-fold as assessed by quantitative PCR (sup-
plemental Fig. S1). ApoA-IV has been closely linked to triglyceride
metabolism, and apoC-II is a requisite cofactor for lipoprotein lipase
activity and uptake of free fatty acids into extrahepatic tissues. Given the
importance of apolipoproteins in lipid metabolism and their regulation
by PGC-1 in vitro, we next investigated the role of PGC-1 in the
regulation of triglyceride levels in vivo.
Hepatic PGC-1 Levels Influence Serum and VLDL Triglyceride
Levels—We assessed apolipoprotein and lipid levels in vivo following
either acute gain or loss of PGC-1 function. Adenoviral PGC-1 or
adenoviral RNAi targeting PGC-1 was infused into the tail veins of
mice and their hepatic mRNAs collected 5 days later immediately fol-
lowing a 24-h fast during which endogenous PGC-1 was induced.
Fig. 5A demonstrates that forced expression of PGC-1 causes a
roughly 2-fold increase in mRNA levels for apolipoproteins A-IV and
C-II compared with control mice and a modest increase in apoC-III
expression. These transcriptional events occur in parallel with a 4-fold
increase in serum triglyceride level (Fig. 5B). We next measured the
triglyceride content of VLDL, because this lipoprotein is the major car-
rier of triglyceride in the endogenous pathway of lipid transport. Fast
protein liquid chromatography lipoprotein fractionation and triglycer-
ide measurement display an2-fold increase in triglyceride content in
the VLDL fraction of mice receiving adenoviral PGC-1 (Fig. 5C ).
Tail vein delivery of adenoviral RNAi, which knocks down PGC-1
expression in vivo (34), allows examination of the requirement for
PGC-1 in lipoprotein metabolism. Injection of this RNAi results in a
70% decrease in PGC-1 mRNA versus control mice and concomitant
decreases in apoA-IV and C-II of 50 and 40%, respectively (Fig. 5A,
supplemental Fig. S2). Analysis of serum taken from PGC-1 knock-
downmice reveals a significant decrease in total serum triglyceride level
(Fig. 5B) as well as a 2-fold decrease in VLDL triglyceride (Fig. 5C ).
FIGURE 4. Fasting induces hepatic mRNA for PGC-1, apoA-IV, and apoC-II. Mice
were fasted for 6 and 24 h and sacrificed or refed for another 24 h and then sacrificed.
Liver mRNA was analyzed for PGC-1 and apolipoprotein transcript levels via Northern
blotting using radiolabeledmouse cDNA probes. 36B4 was blotted as a loading control.
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These data together support an important role for PGC-1 in regulating
hepatic lipoprotein export.
DISCUSSION
Given the versatile roles in liver biology attributed to both PGC-1
and HNF4, we looked for genes with a particular requirement for the
combination of these two factors. We found that PGC-1 and HNF4
robustly target a subset of apolipoproteins in F9 stem cells and human
and mouse hepatoma cells. These apolipoproteins are involved in the
metabolism of VLDL, the major carrier of hepatic triglyceride, and are
induced during fasting. Forced expression of PGC-1 in vivo induces
these apolipoproteins and increases both serum and VLDL triglyceride
levels. Knock down of PGC-1 in vivo leads to a parallel decrease in
apolipoprotein expression and reduced serum and VLDL triglyceride.
Liver-specific HNF4 knock-out mice also suffer from a loss of these
same apolipoproteins and dramatically reduced serum lipid levels (19).
It is likely that PGC-1 coactivation of HNF4 serves as a critical reg-
ulatory step in hepatic apolipoprotein induction and lipoprotein export
during fasting.
The screen used to identify the targets of HNF4 and PGC-1 coop-
erative actionwas performed in pluripotent F9 teratocarcinoma cells. In
this unbiased cellular context, there is presumably little expression of
other liver-enriched transcription factors. In essence, we detect only
those genes whose induction minimally requires the ectopic expression
of PGC-1 and HNF4. Although apolipoproteins A-I, A-IV, C-II, and
C-III have been previously identified asHNF4 targets (31, 35–37), they
are induced robustly only with co-expressed PGC-1. These data sug-
gest that HNF4 requires PGC-1 to realize its full transcriptional
potential. Interestingly, other known targets of PGC-1 and HNF4,
such as glucose-6-phosphatase and phosphoenolpyruvate carboxyki-
nase, did not score high in our screen. One possible explanation is that
these gluconeogenic genes have more complex promoters that require
the presence of other transcription factors for their activation. For
instance, cAMP-response element-binding protein, glucocorticoid
receptor, and FOXO1 all bind gluconeogenic promoters, and PGC-1
cannot induce phosphoenolpyruvate carboxykinase or glucose-6-phos-
phatase if FOXO1 is inactive (11).
Another important consideration is that several HNF4 targets, such
FIGURE 5. Apolipoprotein mRNA levels, VLDL triglyceride levels, and serum triglyceride levels were determined in vivo by PGC-1. Mice were tail vein injected with
adenovirus encoding PGC-1, a scrambled RNAi control, or an RNAi that targets and knocks down PGC-1 transcript. Livers and plasmawere harvested. A, liver mRNAwas analyzed
for PGC-1 and apolipoprotein transcript levels via Northern blotting using radiolabeled mouse cDNA probes. 36B4 was blotted as a loading control. B, serum was separated from
other plasma components and analyzed for triglyceride content. Data represent the mean S.E. *, p0.01; **, p0.001. C, serum was subjected to fast protein liquid chromatog-
raphy to fractionate lipoprotein classes. VLDL fractions were collected and analyzed for triglyceride content. Data represent mean S.E.
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as apoB, apoE, and E-cadherin, are not further increased by expression
of PGC-1. Although themechanism for this selective effect of PGC-1
on HNF4 target genes is unknown, PGC-1may confer a subtle con-
formational change upon its partner transcription factor that affects its
ability to bind certain sequences of DNA. Alternatively, small differ-
ences in response elements in promoters may determine whether a
productive interaction occurs between a bound transcription factor and
a coactivator. It has recently been shown that DNA sequence variation
in B sites dictates which coactivators will interact with bound NF-B
(38). This implies that promoter response elements hold transcription
factors in very specific conformations.
These results underscore the roles of apolipoproteins and lipoprotein
assembly in the fasted liver. During fasting, mobilization of free fatty
acids from adipose tissue and their influx into the liver produce a
marked steatosis. Whereas free fatty acids serve as substrate for -oxi-
dation to acetyl CoA and subsequent conversion into ketone bodies,
excess free fatty acids can be re-esterified into triglycerides for lipopro-
tein export and extrahepatic utilization (39). In fact, triglyceride synthe-
sis is actually increased in the fasted liver (40, 41). In addition, fasting
presumes a complete halt in the exogenous supply of dietary lipids from
the intestine. In this case, de novo synthesis of VLDL from the liver
becomes the primary source of triglyceride and cholesterol delivery to
peripheral tissues. Increased lipoprotein assembly and export in the
liver during fasting are reflected in the elevated levels of apolipoproteins
A-I, A-IV, and C-II, in part mediated by PGC-1.
It has been shown previously that alterations in apolipoprotein syn-
thesis per se can affect lipid homeostasis. ApoA-IV knock-outmice have
greatly reduced plasma triglyceride and VLDL levels (42). Transgenic
studies in which human apolipoproteins A-IV, C-II, and C-III are over-
expressed in mice all lead to severe hypertriglyceridemia (43–45). Fur-
thermore, apoC-III regulates liver VLDL synthesis in an insulin-respon-
sive manner. Insulin normally inhibits the secretion of VLDL into the
systemic circulation (46), and diabetic hypertriglyceridemia is due in
part to the loss of insulin down-regulation of apoC-III (47, 48). Con-
comitant defects in both glucose and lipid homeostasis are common in
the diabetic state and increase the risk of cardiovascular disease in the
“metabolic syndrome” (49). Indeed, variation in the apoA-I/C-III/A-IV
gene cluster has been heavily associated with familial combined hyper-
lipidemia, estimated to cause 10–20% of all premature coronary heart
disease (50–52).
Because PGC-1 coactivation of HNF4 is an important step in
hepatic triglyceride release, modulation of PGC-1 binding to HNF4
may provide a novel therapy to manage the dyslipidemia of insulin
resistance. Chemical inhibitors that selectively disrupt the docking of
HNF4 to PGC-1may have therapeutic benefit in preventing diabetic
hyperglycemia, hyperlipidemia, and other cardiac risk factors. Para-
digms for such inhibition already exist in normal physiology; it has been
reported that bile acids disrupt the binding ofHNF4 to PGC-1 as part
of a negative feedback loop in bile acid synthesis (3). It is possible that
small molecules that bind the ligand pocket of HNF4 may alter its
recruitment to PGC-1, just as some agonists of the glucocorticoid
receptor affect its docking to the coactivator GRIP1 (53).
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